Nhận Dạng Quốc Tế & Đặc Tính Hóa Học
Monoisotopic mass
248.152477894
InChI
InChI=1S/C14H20N2O2/c1-10(2)16-8-11(17)9-18-14-5-3-4-13-12(14)6-7-15-13/h3-7,10-11,15-17H,8-9H2,1-2H3
InChI Key
InChIKey=JZQKKSLKJUAGIC-UHFFFAOYSA-N
IUPAC Name
[2-hydroxy-3-(1H-indol-4-yloxy)propyl](propan-2-yl)amine
Traditional IUPAC Name
pindolol
SMILES
CC(C)NCC(O)COC1=CC=CC2=C1C=CN2
pKa (strongest acidic)
14.09
pKa (Strongest Basic)
9.67
Refractivity
71.46 m3·mol-1
Dược Lực Học :
Pindolol is a non-selective beta-adrenergic antagonist (beta-blocker) which possesses intrinsic sympathomimetic activity (ISA) in therapeutic dosage ranges but does not possess quinidine-like membrane stabilizing activity. Pindolol impairs AV node conduction and decreases sinus rate and may also increase plasma triglycerides and decrease HDL-cholesterol levels. Pindolol is nonpolar and hydrophobic, with low to moderate lipid solubility. Pindolol has little to no intrinsic sympathomimetic activity and, unlike some other beta-adrenergic blocking agents, pindolol has little direct myocardial depressant activity and does not have an anesthetic-like membrane-stabilizing action.
Cơ Chế Tác Dụng :
A moderately lipophilic beta blocker (adrenergic beta-antagonists). It is non-cardioselective and has intrinsic sympathomimetic actions, but little membrane-stabilizing activity. (From Martindale, The Extra Pharmocopoeia, 30th ed, p638)
Pindolol non-selectively blocks beta-1 adrenergic receptors mainly in the heart, inhibiting the effects of epinephrine and norepinephrine resulting in a decrease in heart rate and blood pressure. By binding beta-2 receptors in the juxtaglomerular apparatus, Pindolol inhibits the production of renin, thereby inhibiting angiotensin II and aldosterone production and therefore inhibits the vasoconstriction and water retention due to angiotensin II and aldosterone, respectively.
Dược Động Học :
▧ Absorption :
Rapidly and reproducibly absorbed (bioavailability greater than 95%).
▧ Volume of Distribution :
* 2 L/kg
▧ Protein binding :
40%
▧ Metabolism :
Hepatic. In man, 35% to 40% is excreted unchanged in the urine and 60% to 65% is metabolized primarily to hydroxy-metabolites which are excreted as glucuronides and ethereal sulfates.
▧ Route of Elimination :
Pindolol undergoes extensive metabolism in animals and man. In man, 35% to 40% is excreted unchanged in the urine and 60% to 65% is metabolized primarily to hydroxy-metabolites which are excreted as glucuronides and ethereal sulfates. About 6% to 9% of an administered intravenous dose is excreted by the bile into the feces.
▧ Half Life :
3 to 4 hours
▧ Clearance :
* 50-300 mL/min [cirrhotic patients]
Độc Tính :
LD50=263 mg/kg (orally in rats). Signs of overdose include excessive bradycardia, cardiac failure, hypotension, and bronchospasm.
Chỉ Định :
For the management of hypertension, edema, ventricular tachycardias, and atrial fibrillation.
Tương Tác Thuốc :
-
Acetohexamide
The beta-blocker, pindolol, may decrease symptoms of hypoglycemia.
-
Aminophylline
Antagonism of action and increased effect of theophylline
-
Chlorpromazine
Increased effect of both drugs
-
Chlorpropamide
The beta-blocker, pindolol, may decrease symptoms of hypoglycemia.
-
Clonidine
Increased hypertension when clonidine stopped
-
Dihydroergotamine
Ischemia with risk of gangrene
-
Diltiazem
Increased risk of bradycardia
-
Disopyramide
The beta-blocker, pindolol, may increase the toxicity of disopyramide.
-
Dyphylline
Antagonism of action and increased effect of theophylline
-
Epinephrine
Hypertension, then bradycardia
-
Ergonovine
Ischemia with risk of gangrene
-
Ergotamine
Ischemia with risk of gangrene
-
Fenoterol
Antagonism
-
Formoterol
Antagonism
-
Gliclazide
The beta-blocker, pindolol, may decrease symptoms of hypoglycemia.
-
Glipizide
The beta-blocker, pindolol, may decrease symptoms of hypoglycemia.
-
Glisoxepide
The beta-blocker, pindolol, may decrease symptoms of hypoglycemia.
-
Glyburide
The beta-blocker, pindolol, may decrease symptoms of hypoglycemia.
-
Glycodiazine
The beta-blocker, pindolol, may decrease symptoms of hypoglycemia.
-
Ibuprofen
Risk of inhibition of renal prostaglandins
-
Indomethacin
Risk of inhibition of renal prostaglandins
-
Insulin Glargine
The beta-blocker, pindolol, may decrease symptoms of hypoglycemia.
-
Isoprenaline
Antagonism
-
Lidocaine
The beta-blocker increases the effect and toxicity of lidocaine
-
Mesoridazine
Increased risk of cardiotoxicity and arrhythmias
-
Methyldopa
Possible hypertensive crisis
-
Methysergide
Ischemia with risk of gangrene
-
Orciprenaline
Antagonism
-
Oxtriphylline
Antagonism of action and increased effect of theophylline
-
Pipobroman
Antagonism
-
Pirbuterol
Antagonism
-
Piroxicam
Risk of inhibition of renal prostaglandins
-
Prazosin
Risk of hypotension at the beginning of therapy
-
Procaterol
Antagonism
-
Repaglinide
The beta-blocker, pindolol, may decrease symptoms of hypoglycemia.
-
Salbutamol
Antagonism
-
Salmeterol
Antagonism
-
Terazosin
Increased risk of hypotension. Initiate concomitant therapy cautiously.
-
Terbutaline
Antagonism
-
Theophylline
Antagonism of action and increased effect of theophylline
-
Thioridazine
Increased risk of cardiotoxicity and arrhythmias
-
Tolazamide
The beta-blocker, pindolol, may decrease symptoms of hypoglycemia.
-
Tolbutamide
The beta-blocker, pindolol, may decrease symptoms of hypoglycemia.
-
Treprostinil
Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
-
Verapamil
Increased effect of both drugs
Liều Lượng & Cách Dùng :
Tablet - Oral
Dữ Kiện Thương Mại
Giá thị trường
-
Giá bán buôn : USD >1.0
Đơn vị tính : tablet
-
Giá bán buôn : USD >1.05
Đơn vị tính : tablet
-
Giá bán buôn : USD >1.52
Đơn vị tính : tablet
-
Giá bán buôn : USD >0.24
Đơn vị tính : tablet
-
Giá bán buôn : USD >0.24
Đơn vị tính : tablet
-
Giá bán buôn : USD >0.24
Đơn vị tính : tablet
-
Giá bán buôn : USD >0.24
Đơn vị tính : tablet
-
Giá bán buôn : USD >0.24
Đơn vị tính : tablet
-
Giá bán buôn : USD >0.24
Đơn vị tính : tablet
-
Giá bán buôn : USD >0.42
Đơn vị tính : tablet
-
Giá bán buôn : USD >0.42
Đơn vị tính : tablet
-
Giá bán buôn : USD >0.42
Đơn vị tính : tablet
-
Giá bán buôn : USD >0.42
Đơn vị tính : tablet
-
Giá bán buôn : USD >0.42
Đơn vị tính : tablet
-
Giá bán buôn : USD >0.42
Đơn vị tính : tablet
-
Giá bán buôn : USD >0.61
Đơn vị tính : tablet
-
Giá bán buôn : USD >0.61
Đơn vị tính : tablet
-
Giá bán buôn : USD >0.61
Đơn vị tính : tablet
-
Giá bán buôn : USD >0.61
Đơn vị tính : tablet
-
Giá bán buôn : USD >0.61
Đơn vị tính : tablet
-
Giá bán buôn : USD >0.61
Đơn vị tính : tablet
-
Giá bán buôn : USD >0.61
Đơn vị tính : tablet
-
Giá bán buôn : USD >0.73
Đơn vị tính : tablet
Nhà Sản Xuất
-
Sản phẩm biệt dược : Betapindol
-
Sản phẩm biệt dược : Blockin L
-
Sản phẩm biệt dược : Blocklin L
-
Sản phẩm biệt dược : Calvisken
-
Sản phẩm biệt dược : Decreten
-
Sản phẩm biệt dược : Durapindol
-
Sản phẩm biệt dược : Glauco-Visken
-
Sản phẩm biệt dược : Pectobloc
-
Sản phẩm biệt dược : Pinbetol
-
Sản phẩm biệt dược : Prinodolol
-
Sản phẩm biệt dược : Pynastin
-
Sản phẩm biệt dược : Visken
Tài Liệu Tham Khảo Thêm
National Drug Code Directory